Future prospects and challenges of antiangiogenic cancer gene therapy

Human Gene Therapy

Volumn 21, Issue 4, 2010, Pages 381-396

  Samaranayake, Haritha ^a,b   Määttä, Ann Marie ^a   Pikkarainen, Jere ^a,b   Ylä Herttuala, Seppo ^b,c  

^a Finland Ark Therapeutics Oy   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTEGRIN; ANGIOGENESIS INHIBITOR; ANGIOGENIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOSTATIN; CATHEPSIN; COPPER; ENDOTHELIN; EPIDERMAL GROWTH FACTOR; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR; GANCICLOVIR; GELATINASE A; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; NITRIC OXIDE; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN E; SCATTER FACTOR; STROMELYSIN; THROMBOCYTE ACTIVATING FACTOR; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BLEEDING; CANCER GENE THERAPY; COLON CARCINOMA; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERTENSION; IMMUNE SYSTEM; KIDNEY DYSFUNCTION; LIVER METASTASIS; LUNG METASTASIS; MELANOMA; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEINURIA; REVIEW; THROMBOSIS; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; FEMALE; GENE THERAPY; HUMANS; MALE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77950961700     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2010.017     Document Type: Review

References (185)

1. Abe, T., Terada, K., Wakimoto, H., Inoue, R., Tyminski, E., Bookstein, R., Basilion, J.P., and Chiocca, E.A. (2003). PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res. 63, 2300-2305.
2. Asselin-Paturel, C., Lassau, N., Guinebretiere, J.M., Zhang, J., Gay, F., Bex, F., Hallez, S., Leclere, J., Peronneau, P., Mami-Chouaib, F., and Chouaib, S. (1999). Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonogra-phy. Gene Ther. 6, 606-615.
3. Baish, J.W., Netti, P.A., and Jain, R.K. (1997). Transmural coupling of fluid flow in microcirculatory network and inter-stitium in tumors. Microvasc. Res. 53, 128-141.
4. Benjamin, L.E., and Keshet, E. (1997). Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl. Acad. Sci. U.S.A. 94, 8761-8766.
5. Bergers, G., and Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603.
6. Berkman, R.A., Merrill, M.J., Reinhold, W.C., Monacci, W.T., Saxena, A., Clark, W.C., Robertson, J.T., Ali, I.U., and Oldfield, E.H. (1993). Expression of the vascular permeability factor= vascular endothelial growth factor gene in central nervous system neoplasms. J. Clin. Invest. 91, 153-159.
7. Boucher, Y., and Jain, R.K. (1992). Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: Implications for vascular collapse. Cancer Res. 52, 5110-5114.
8. Boucher, Y., Salehi, H., Witwer, B., Harsh, G.R., and Jain, R.K. (1997). Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br. J. Cancer 75, 829-836.
9. Byrnes, A.P., Rusby, J.E., Wood, M.J., and Charlton, H.M. (1995). Adenovirus gene transfer causes inflammation in the brain. Neuroscience 66, 1015-1024.
10. Calvo, A., Feldman, A.L., Libutti, S.K., and Green, J.E. (2002). Adenovirus-mediated endostatin delivery results in inhibition of mammary gland tumor growth in C3(1)=SV40 T-antigen transgenic mice. Cancer Res. 62, 3934-3938.
11. Carmeliet, P. (2005). Angiogenesis in life, disease and medicine. Nature 438, 932-936.
12. Carmeliet, P., and Jain, R.K. (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257.
13. Chen, C.T., Lin, J., Li, Q., Phipps, S.S., Jakubczak, J.L., Stewart, D.A., Skripchenko, Y., Forry-Schaudies, S., Wood, J., Schnell, C., and Hallenbeck, P.L. (2000). Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Hum. Gene Ther. 11, 1983-1996.
14. Chen, Q.R., Kumar, D., Stass, S.A., and Mixson, A.J. (1999). Li-posomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res. 59, 3308-3312.
15. Chen, Q.R., Zhang, L., Gasper, W., and Mixson, A.J. (2001). Targeting tumor angiogenesis with gene therapy. Mol. Genet. Metab. 74, 120-127.
16. Claes, A., Wesseling, P., Jeuken, J., Maass, C., Heerschap, A., and Leenders, W.P. (2008). Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol. Cancer Ther. 7, 71-78.
17. Crystal, R.G. (1999). In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors. Cancer Chemother. Pharmacol. 43(Suppl.), S90-S99.
18. Dai, Y., Schwarz, E.M., Gu, D., Zhang, W.W., Sarvetnick, N., and Verma, I.M. (1995). Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U.S.A. 92, 1401-1405.
19. De, P.M., Venneri, M.A., Roca, C., and Naldini, L. (2003). Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 9, 789-795.
20. Deane, B.R., and Lantos, P.L. (1981a). The vasculature of experimental brain tumours. 1. A sequential light and electron microscope study of angiogenesis. J. Neurol. Sci. 49, 55-66.
21. Deane, B.R., and Lantos, P.L. (1981b). The vasculature of experimental brain tumours. 2. A quantitative assessment of morphological abnormalities. J. Neurol. Sci. 49, 67-77.
22. Dell'Eva, R., Pfeffer, U., Indraccolo, S., Albini, A., and Noonan, D. (2002). Inhibition of tumor angiogenesis by angiostatin: From recombinant protein to gene therapy. Endothelium 9, 3-10.
23. Dias, S., Hattori, K., Zhu, Z., Heissig, B., Choy, M., Lane, W., Wu, Y., Chadburn, A., Hyjek, E., Gill, M., Hicklin, D.J., Witte, L., Moore, M.A., and Rafii, S. (2000). Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. 106, 511-521.
24. Dias, S., Hattori, K., Heissig, B., Zhu, Z., Wu, Y., Witte, L., Hicklin, D.J., Tateno, M., Bohlen, P., Moore, M.A., and Rafii, S. (2001). Inhibition of both paracrine and autocrine VEGF= VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc. Natl. Acad. Sci. U.S.A. 98, 10857-10862.
25. Dikov, M.M., Ohm, J.E., Ray, N., Tchekneva, E.E., Burlison, J., Moghanaki, D., Nadaf, S., and Carbone, D.P. (2005). Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J. Immunol. 174, 215-222.
26. Ding, I., Sun, J.Z., Fenton, B., Liu, W.M., Kimsely, P., Okunieff, P., and Min, W. (2001). Intratumoral administration of en-dostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Cancer Res. 61, 526-531.
27. Dome, B., Hendrix, M.J., Paku, S., Tovari, J., and Timar, J. (2007). Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am. J. Pathol. 170, 1-15.
28. Driesse, M.J., Vincent, A.J., Sillevis Smitt, P.A., Kros, J.M., Hoogerbrugge, P.M., Avezaat, C.J., Valerio, D., and Bout, A. (1998). Intracerebral injection of adenovirus harboring the HSVtk gene combined with ganciclovir administration: Toxi-city study in nonhuman primates. Gene Ther. 5, 1122-1129.
29. Duda, D.G., Cohen, K.S., Kozin, S.V., Perentes, J.Y., Fukumura, D., Scadden, D.T., and Jain, R.K. (2006). Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood 107, 2774-2776.
30. Ebos, J.M., Lee, C.R., Cruz-Munoz, W., Bjarnason, G.A., Chris-tensen, J.G., and Kerbel, R.S. (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239.
31. Ellis, L.M., and Hicklin, D.J. (2008). VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat. Rev. Cancer 8, 579-591.
32. Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., Gorbunova, V., Bay, J.O., Bodrogi, I., Jagiello-Gruszfeld, A., and Moore, N. (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 370, 2103-2111.
33. Ferrara, N. (2002). VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2, 795-803.
34. Ferrara, N., and Davis-Smyth, T. (1997). The biology of vascular endothelial growth factor. Endocr. Rev. 18, 4-25.
35. Ferrara, N., and Bunting, S. (1996). Vascular endothelial growth factor, a specific regulator of angiogenesis. Curr. Opin. Ne-phrol. Hypertens. 5, 35-44. (Pubitemid 26088560)
36. Ferrara, N., Gerber, H.P., and LeCouter, J. (2003). The biology of VEGF and its receptors. Nat. Med. 9, 669-676.
37. Folberg, R., Hendrix, M.J., and Maniotis, A.J. (2000). Vasculo-genic mimicry and tumor angiogenesis. Am. J. Pathol. 156, 361-381.
38. Folkman, J. (1971). Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285, 1182-1186.
39. Folkman, J., and Shing, Y. (1992). Angiogenesis. J. Biol. Chem. 267, 10931-10934.
40. Fragoso, R., Pereira, T., Wu, Y., Zhu, Z., Cabecadas, J., and Dias, S. (2006). VEGFR-1 (FLT-1) activation modulates acute lym-phoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood 107, 1608-1616.
41. Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., and Carbone, D.P. (1998). Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hemato-poietic lineages in vivo. Blood 92, 4150-4166.
42. Gabrilovich, D.I., Chen, H.L., Girgis, K.R., Cunningham, H.T., Meny, G.M., Nadaf, S., Kavanaugh, D., and Carbone, D.P. (1996). Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2, 1096-1103.
43. Gao, Z.N., Wei, Y.Q., Yang, P.S., Xu, X., Zhao, H.Q., Huan, X., and Kang, B. (2007). Combined effects of soluble vascular endothelial growth factor receptor FLT-1 gene therapy and cisplatin chemotherapy in human tongue carcinoma xeno-grafts. Oral Oncol. 43, 477-483.
44. Garkavtsev, I., Kozin, S.V., Chernova, O., Xu, L., Winkler, F., Brown, E., Barnett, G.H., and Jain, R.K. (2004). The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428, 328-332.
45. Goldman, C.K., Kendall, R.L., Cabrera, G., Soroceanu, L., Heike, Y., Gillespie, G.Y., Siegal, G.P., Mao, X., Bett, A.J., Huckle, W.R., Thomas, K.A., and Curiel, D.T. (1998). Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl. Acad. Sci. U.S.A. 95, 8795-8800.
46. Gomez-Manzano, C., Holash, J., Fueyo, J., Xu, J., Conrad, C.A., Aldape, K.D., de Groot, J.F., Bekele, B.N., and Yung, W.K. (2008). VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol. 10, 940-945.
47. Gondi, C.S., Lakka, S.S., Yanamandra, N., Siddique, K., Dinh, D.H., Olivero, W.C., Gujrati, M., and Rao, J.S. (2003). Expression of antisense uPAR and antisense uPA from a bicis-tronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene 22, 5967-5975.
48. Gondi, C.S., Lakka, S.S., Dinh, D.H., Olivero, W.C., Gujrati, M., and Rao, J.S. (2004a). RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 23, 8486-8496.
49. Gondi, C.S., Lakka, S.S., Yanamandra, N., Olivero, W.C., Dinh, D.H., Gujrati, M., Tung, C.H., Weissleder, R., and Rao, J.S. (2004b). Adenovirus-mediated expression of antisense uroki-nase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res. 64, 4069-4077.
50. Hajitou, A., Grignet, C., Devy, L., Berndt, S., Blacher, S., Deroanne, C.F., Bajou, K., Fong, T., Chiang, Y., Foidart, J.M., and Noel, A. (2002). The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J. 16, 1802-1804.
51. Hampl, M., Tanaka, T., Albert, P.S., Lee, J., Ferrari, N., and Fine, H.A. (2001). Therapeutic effects of viral vector-mediated an-tiangiogenic gene transfer in malignant ascites. Hum. Gene Ther. 12, 1713-1729.
52. Harding, T.C., Lalani, A.S., Roberts, B.N., Yendluri, S., Luan, B., Koprivnikar, K.E., Gonzalez-Edick, M., Huan-Tu, G., Musterer, R., VanRoey, M.J., Ozawa, T., LeCouter, R.A., Deen, D., Dickinson, P.J., and Jooss, K. (2006). AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma. Mol. Ther. 13, 956-966.
53. Hasumi, Y., Mizukami, H., Urabe, M., Kohno, T., Takeuchi, K., Kume, A., Momoeda, M., Yoshikawa, H., Tsuruo, T., Shibuya, M., Taketani, Y., and Ozawa, K. (2002). Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res. 62, 2019-2023.
54. Heidenreich, R., Machein, M., Nicolaus, A., Hilbig, A., Wild, C., Clauss, M., Plate, K.H., and Breier, G. (2004). Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants. Int. J. Cancer 111, 348-357.
55. Hlatky, L., Hahnfeldt, P., and Folkman, J. (2002). Clinical application of antiangiogenic therapy: Microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst. 94, 883-893.
56. Holash, J., Maisonpierre, P.C., Compton, D., Boland, P., Alexander, C.R., Zagzag, D., Yancopoulos, G.D., and Wiegand, S.J. (1999). Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994-1998.
57. Im, S.A., Gomez-Manzano, C., Fueyo, J., Liu, T.J., Ke, L.D., Kim, J.S., Lee, H.Y., Steck, P.A., Kyritsis, A.P., and Yung, W.K. (1999). Antiangiogenesis treatment for gliomas: Transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res. 59, 895-900.
58. Isayeva, T., Chanda, D., Kallman, L., Eltoum, I.E., and Ponnaz-hagan, S. (2007a). Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res. 67, 5789-5797.
59. Isayeva, T., Ren, C., and Ponnazhagan, S. (2007b). Intraperi-toneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway. Gene Ther. 14, 138-146.
60. Ishikawa, H., Nakao, K., Matsumoto, K., Ichikawa, T., Hama-saki, K., Nakata, K., and Eguchi, K. (2003). Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene. Hepatology 37, 696-704.
61. Jain, R.K. (1998). The next frontier of molecular medicine: Delivery of therapeutics. Nat. Med. 4, 655-657.
62. Jain, R.K. (2003). Molecular regulation of vessel maturation. Nat. Med. 9, 685-693.
63. Jain, R.K., di Tomaso, E., Duda, D.G., Loeffler, J.S., Sorensen, A.G., and Batchelor, T.T. (2007). Angiogenesis in brain tumours. Nat. Rev. Neurosci. 8, 610-622.
64. Jensen, R.L., Ragel, B.T., Whang, K., and Gillespie, D. (2006). Inhibition of hypoxia inducible factor-1a (HIF-1a) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J. Neurooncol. 78, 233-247.
65. Jin, F., Xie, Z., Kuo, C.J., Chung, L.W., and Hsieh, C.L. (2005). Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy. Cancer Gene Ther. 12, 257-267.
66. Jin, X., Bookstein, R., Wills, K., Avanzini, J., Tsai, V., LaFace, D., Terracina, G., Shi, B., and Nielsen, L.L. (2001). Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo. Cancer Gene Ther. 8, 982-989.
67. Kajiwara, K., Byrnes, A.P., Charlton, H.M., Wood, M.J., and Wood, K.J. (1997). Immune responses to adenoviral vectors during gene transfer in the brain. Hum. Gene Ther. 8, 253-265.
68. Kerbel, R.S. (2008). Tumor angiogenesis. N. Engl. J. Med. 358, 2039-2049.
69. Kerbel, R.S., and Kamen, B.A. (2004). The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4, 423-436.
70. Kim, K.S., and Park, Y.S. (2005). Antitumor effects of angio-statin K1-3 and endostatin genes coadministered by the hydrodynamics-based transfection method. Oncol. Res. 15, 343-350.
71. Kim, K.S., Kim, H.S., Park, J.S., Kwon, Y.G., and Park, Y.S. (2004). Inhibition of B16BL6 tumor progression by coadmin-istration of recombinant angiostatin K1-3 and endostatin genes with cationic liposomes. Cancer Gene Ther. 11, 441-449.
72. Kirsch, M., Schackert, G., and Black, P.M. (2000). Anti-angiogenic treatment strategies for malignant brain tumors. J. Neurooncol. 50, 149-163. (Pubitemid 32166297)
73. Kong, H.L., and Crystal, R.G. (1998a). Gene therapy strategies for tumor antiangiogenesis. J. Natl. Cancer Inst. 90, 273-286.
74. Kong, H.L., Hecht, D., Song, W., Kovesdi, I., Hackett, N.R., Yayon, A., and Crystal, R.G. (1998b). Regional suppression of tumor growth by invivo transfer of a cDNA encodinga secreted form of the extracellular domain of the Flt-1 vascular endo-thelial growth factor receptor. Hum. Gene Ther. 9, 823-833.
75. Kremer, E.J., and Perricaudet, M. (1995). Adenovirus and adeno-associated virus mediated gene transfer. Br. Med. Bull. 51, 31-44.
76. Kuhnert, F., Tam, B.Y., Sennino, B., Gray, J.T., Yuan, J., Jocson, A., Nayak, N.R., Mulligan, R.C., McDonald, D.M., and Kuo, C.J. (2008). Soluble receptor-mediated selective inhibition of VEGFR and PDGFRb signaling during physiologic and tumor angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 105, 10185-10190.
77. Kulke, M.H., Bergsland, E.K., Ryan, D.P., Enzinger, P.C., Lynch, T.J., Zhu, A.X., Meyerhardt, J.A., Heymach, J.V., Fogler, W.E., Sidor, C., Michelini, A., Kinsella, K., Venook, A.P., and Fuchs, C.S. (2006). Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 24, 3555-3561. (Pubitemid 46630526)
78. Kumai, Y., Ooboshi, H., Ibayashi, S., Ishikawa, E., Sugimori, H., Kamouchi, M., Kitazono, T., Egashira, K., and Iida, M. (2007). Postischemic gene transfer of soluble Flt-1 protects against brain ischemia with marked attenuation of blood-brain barrier permeability. J. Cereb. Blood Flow Metab. 27, 1152-1160.
79. Kunkel, P., Ulbricht, U., Bohlen, P., Brockmann, M.A., Fill-brandt, R., Stavrou, D., Westphal, M., and Lamszus, K. (2001). Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 61, 6624-6628.
80. Kuo, C.J., Farnebo, F., Yu, E.Y., Christofferson, R., Swearingen, R.A., Carter, R., von Recum, H.A., Yuan, J., Kamihara, J., Flynn, E., D'Amato, R., Folkman, J., and Mulligan, R.C. (2001). Comparative evaluation of the antitumor activity of anti-angiogenic proteins delivered by gene transfer. Proc. Natl. Acad. Sci. U.S.A. 98, 4605-4610.
81. Kurup, A., Lin, C.W., Murry, D.J., Dobrolecki, L., Estes, D., Yiannoutsos, C.T., Mariano, L., Sidor, C., Hickey, R., and Hanna, N. (2006). Recombinant human angiostatin (rhAn-giostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: A phase II study from Indiana University. Ann. Oncol. 17, 97-103.
82. Kusmartsev, S., and Gabrilovich, D.I. (2002). Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol. Immunother. 51, 293-298.
83. Kuwana, M., Okazaki, Y., Kodama, H., Satoh, T., Kawakami, Y., and Ikeda, Y. (2006). Endothelial differentiation potential of human monocyte-derived multipotential cells. Stem Cells 24, 2733-2743.
84. Lakka, S.S., Gondi, C.S., Yanamandra, N., Dinh, D.H., Olivero, W.C., Gujrati, M., and Rao, J.S. (2003). Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth. Cancer Res. 63, 2454-2461.
85. Lammering, G., Hewit, T.H., Valerie, K., Lin, P.S., Contessa, J.N., and Schmidt-Ullrich, R.K. (2003). Anti-erbB receptor strategy as a gene therapeutic intervention to improve radiotherapy in malignant human tumours. Int. J. Radiat. Biol. 79, 561-568.
86. Lee, K.D., Pitas, R.E., and Papahadjopoulos, D. (1992). Evidence that the scavenger receptor is not involved in the uptake of negatively charged liposomes by cells. Biochim. Biophys. Acta 1111, 1-6.
87. Lee, T.H., Seng, S., Sekine, M., Hinton, C., Fu, Y., Avraham, H.K., and Avraham, S. (2007). Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1=FLT1. PLoS Med. 4, e186.
88. Leenders, W.P., Kusters, B., Verrijp, K., Maass, C., Wesseling, P., Heerschap, A., Ruiter, D., Ryan, A., and de Waal, R. (2004). Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin. Cancer Res. 10, 6222-6230.
89. Li, B., Lalani, A.S., Harding, T.C., Luan, B., Koprivnikar, K., Huan, T.G., Prell, R., VanRoey, M.J., Simmons, A.D., and Jooss, K. (2006). Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res. 12, 6808-6816.
90. Li, L., Huang, J.L., Liu, Q.C., Wu, P.H., Liu, R.Y., Zeng, Y.X., and Huang, W.L. (2004). Endostatin gene therapy for liver cancer by a recombinant adenovirus delivery. World J. Gastroenterol. 10, 1867-1871.
91. Li, L., Gondi, C.S., Dinh, D.H., Olivero, W.C., Gujrati, M., and Rao, J.S. (2007). Transfection with anti-p65 intrabody suppresses invasion and angiogenesis in glioma cells by blocking nuclear factor-kB transcriptional activity. Clin. Cancer Res. 13, 2178-2190.
92. Li, X., Fu, G.F., Fan, Y.R., Shi, C.F., Liu, X.J., Xu, G.X., and Wang, J.J. (2003). Potent inhibition of angiogenesis and liver tumor growth by administration of an aerosol containing a transferrin-liposome-endostatin complex. World J. Gastro-enterol. 9, 262-266.
93. Liu, J., Li, J., Su, C., Huang, B., and Luo, S. (2007). Soluble Fms-like tyrosine kinase-1 expression inhibits the growth of multiple myeloma in nude mice. Acta Biochim. Biophys. Sin. (Shanghai) 39, 499-506.
94. Luo, X., Andres, M.L., Timiryasova, T.M., Fodor, I., Slater, J.M., and Gridley, D.S. (2005a). Radiation-enhanced endostatin gene expression and effects of combination treatment. Tech-nol. Cancer Res. Treat. 4, 193-202.
95. Luo, X., Slater, J.M., and Gridley, D.S. (2005b). Enhancement of radiation effects by pXLG-mEndo in a lung carcinoma model. Int. J. Radiat. Oncol. Biol. Phys. 63, 553-564.
96. Luo, X., Slater, J.M., and Gridley, D.S. (2006). Radiation and endostatin gene therapy in a lung carcinoma model: Pilot data on cells and cytokines that affect angiogenesis and immune status. Technol. Cancer Res. Treat. 5, 135-146.
97. Lyons, J.A., Sheahan, B.J., Galbraith, S.E., Mehra, R., Atkins, G.J., and Fleeton, M.N. (2007). Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice. Gene Ther. 14, 503-513.
98. Ma, H.I., Lin, S.Z., Chiang, Y.H., Li, J., Chen, S.L., Tsao, Y.P., and Xiao, X. (2002). Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector. Gene Ther. 9, 2-11.
99. Ma, J., Pulfer, S., Li, S., Chu, J., Reed, K., and Gallo, J.M. (2001). Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 61, 5491-5498.
100. Machein, M.R., Risau, W., and Plate, K.H. (1999). Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2. Hum. Gene Ther. 10, 1117-1128.
101. Mae, M., and Crystal, R.G. (2002). Gene transfer to the pleural mesothelium as a strategy to deliver proteins to the lung parenchyma. Hum. Gene Ther. 13, 1471-1482.
102. Mae, M., O'Connor, T.P., and Crystal, R.G. (2005). Gene transfer of the vascular endothelial growth factor receptor Flt-1 suppresses pulmonary metastasis associated with lung growth. Am. J. Respir. Cell Mol. Biol. 33, 629-635.
103. Mahasreshti, P.J., Navarro, J.G., Kataram, M., Wang, M.H., Carey, D., Siegal, G.P., Barnes, M.N., Nettelbeck, D.M., Alvarez, R.D., Hemminki, A., and Curiel, D.T. (2001). Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin. Cancer Res. 7, 2057-2066.
104. Mahasreshti, P.J., Kataram, M., Wang, M.H., Stockard, C.R., Grizzle, W.E., Carey, D., Siegal, G.P., Haisma, H.J., Alvarez, R.D., and Curiel, D.T. (2003). Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin. Cancer Res. 9, 2701-2710.
105. Mahller, Y.Y., Vaikunth, S.S., Ripberger, M.C., Baird, W.H., Saeki, Y., Cancelas, J.A., Crombleholme, T.M., and Cripe, T.P. (2008). Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res. 68, 1170-1179.
106. Maniotis, A.J., Folberg, R., Hess, A., Seftor, E.A., Gardner, L.M., Pe'er, J., Trent, J.M., Meltzer, P.S., and Hendrix, M.J. (1999). Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. Am. J. Pathol. 155, 739-752.
107. McDonald, D.M., Munn, L., and Jain, R.K. (2000). Vasculogenic mimicry: How convincing, how novel, and how significant? Am. J. Pathol. 156, 383-388.
108. Millauer, B., Shawver, L.K., Plate, K.H., Risau, W., and Ullrich, A. (1994). Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576-579.
109. Millauer, B., Longhi, M.P., Plate, K.H., Shawver, L.K., Risau, W., Ullrich, A., and Strawn, L.M. (1996). Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56, 1615-1620.
110. Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E.A., Shenkier, T., Cella, D., and Davidson, N.E. (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for met-astatic breast cancer. N. Engl. J. Med. 357, 2666-2676.
111. Moffat, B.A., Chen, M., Kariaapper, M.S., Hamstra, D.A., Hall, D.E., Stojanovska, J., Johnson, T.D., Blaivas, M., Kumar, M., Chenevert, T.L., Rehemtulla, A., and Ross, B.D. (2006). Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D. Clin. Cancer Res. 12, 1525-1532.
112. Mori, A., Arii, S., Furutani, M., Mizumoto, M., Uchida, S., Furuyama, H., Kondo, Y., Gorrin-Rivas, M.J., Furumoto, K., Kaneda, Y., and Imamura, M. (2000). Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes. Gene Ther. 7, 1027-1033.
113. Morishita, R. (2004). Perspective in progress of cardiovascular gene therapy. J. Pharmacol. Sci. 95, 1-8.
114. Munaut, C., Noel, A., Hougrand, O., Foidart, J.M., Boniver, J., and Deprez, M. (2003). Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int. J. Cancer 106, 848-855.
115. Murdoch, C., and Finn, A. (2000). Chemokine receptors and their role in inflammation and infectious diseases. Blood 95, 3032-3043.
116. Murdoch, C., Muthana, M., Coffelt, S.B., and Lewis, C.E. (2008). The role of myeloid cells in the promotion of tumour angio-genesis. Nat. Rev. Cancer 8, 618-631.
117. Netti, P.A., Roberge, S., Boucher, Y., Baxter, L.T., and Jain, R.K. (1996). Effect of transvascular fluid exchange on pressure-flow relationship in tumors: A proposed mechanism for tumor blood flow heterogeneity. Microvasc. Res. 52, 27-46.
118. Niola, F., Evangelisti, C., Campagnolo, L., Massalini, S., Bue, M.C., Mangiola, A., Masotti, A., Maira, G., Farace, M.G., and Ciafre, S.A. (2006). A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model. Cancer Biol. Ther. 5, 174-179.
119. Ohlfest, J.R., Demorest, Z.L., Motooka, Y., Vengco, I., Oh, S., Chen, E., Scappaticci, F.A., Saplis, R.J., Ekker, S.C., Low, W.C., Freese, A.B., and Largaespada, D.A. (2005). Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the Sleeping Beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glio-blastoma. Mol. Ther. 12, 778-788.
120. Ohm, J.E., and Carbone, D.P. (2001). VEGF as a mediator of tumor-associated immunodeficiency. Immunol. Res. 23, 263-272.
121. Ohm, J.E., and Carbone, D.P. (2002). Immune dysfunction in cancer patients. Oncology 16, 11-18.
122. Ohm, J.E., Gabrilovich, D.I., Sempowski, G.D., Kisseleva, E., Parman, K.S., Nadaf, S., and Carbone, D.P. (2003). VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101, 4878-4886.
123. Ohmoto, Y., Wood, M.J., Charlton, H.M., Kajiwara, K., Perry, V.H., and Wood, K.J. (1999). Variation in the immune response to adenoviral vectors in the brain: Influence of mouse strain, environmental conditions and priming. Gene Ther. 6, 471-481.
124. O'Reilly, M.S. (1997). Angiostatin: An endogenous inhibitor of angiogenesis and of tumor growth. EXS 79, 273-294
125. O'Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M., Lane, W.S., Cao, Y., Sage, E.H., and Folkman, J. (1994). Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [see comments]. Cell 79, 315-328.
126. Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D.P., and Gabrilovich, D.I. (1998). Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kB activation in hemopoietic progenitor cells. J. Immunol. 160, 1224-1232.
127. Paez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Vinals, F., Inoue, M., Bergers, G., Hanahan, D., and Casano-vas, O. (2009). Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231.
128. Peroulis, I., Jonas, N., and Saleh, M. (2002). Antiangiogenic activity of endostatin inhibits C6 glioma growth. Int. J. Cancer 97, 839-845.
129. Persano, L., Moserle, L., Esposito, G., Bronte, V., Barbieri, V., Iafrate, M., Gardiman, M.P., Larghero, P., Pfeffer, U., Nasch-berger, E., Sturzl, M., Indraccolo, S., and Amadori, A. (2009). Interferon-a counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. Carcinogenesis 30, 851-860.
130. Pin, R.H., Reinblatt, M., Bowers, W.J., Federoff, H.J., and Fong, Y. (2004). Herpes simplex virus amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma. J. Gastrointest. Surg. 8, 812-822.
131. Puduvalli, V.K., and Sawaya, R. (2000). Antiangiogenesis: Therapeutic strategies and clinical implications for brain tumors. J. Neurooncol. 50, 189-200.
132. Pulkkanen, K.J., Laukkanen, J.M., Fuxe, J., Kettunen, M.I., Rehn, M., Kannasto, J.M., Parkkinen, J.J., Kauppinen, R.A., Petter-sson, R.F., and Ylä-Herttuala, S. (2002). The combination of HSV-tk and endostatin gene therapy eradicates orthotopic human renal cell carcinomas in nude mice. Cancer Gene Ther. 9, 908-916.
133. Purhonen, S., Palm, J., Rossi, D., Kaskenpaa, N., Rajantie, I., Ylä-Herttuala, S., Alitalo, K., Weissman, I.L., and Salven, P. (2008). Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc. Natl. Acad. Sci. U.S.A. 105, 6620-6625.
134. Raikwar, S.P., Temm, C.J., Raikwar, N.S., Kao, C., Molitoris, B.A., and Gardner, T.A. (2005). Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2: Enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model. Mol. Ther. 12, 1091-1100.
135. Ram, Z., Walbridge, S., Shawker, T., Culver, K.W., Blaese, R.M., and Oldfield, E.H. (1994). The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J. Neurosurg. 81, 256-260.
136. Rao, J.S., Gondi, C., Chetty, C., Chittivelu, S., Joseph, P.A., and Lakka, S.S. (2005). Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol. Cancer Ther. 4, 1399-1408.
137. Reinblatt, M., Pin, R.H., Bowers, W.J., Federoff, H.J., and Fong, Y. (2005). Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor receptor (sFlk-1) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma. Ann. Surg. Oncol. 12, 1025-1036.
138. Ren, C, Kumar, S., Chanda, D., Chen, J., Mountz, J.D., and Ponnazhagan, S. (2008). Therapeutic potential of mesenchymal stem cells producing interferon-a in a mouse melanoma lung metastasis model. Stem Cells 26, 2332-2338.
139. Roy, H., Bhardwaj, S., and Yla-Herttuala, S. (2006). Biology of vascular endothelial growth factors. FEBS Lett. 580,2879-2887.
140. Rubenstein, J.L., Kim, J., Ozawa, T., Zhang, M., Westphal, M., Deen, D.F., and Shuman, M.A. (2000). Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2, 306-314.
141. Sakariassen, P.O., Prestegarden, L., Wang, J., Skaftnesmo, K.O., Mahesparan, R., Molthoff, C, Sminia, P., Sundlisaeter, E., Misra, A., Tysnes, B.B., Chekenya, M., Peters, H., Lende, G., Kalland, K.H., Oyan, A.M., Petersen, K., Jonassen, I., van der, K.A., Feuerstein, B.G., Terzis, A.J., Bjerkvig, R., and Enger, P.O. (2006). Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc. Natl. Acad. Sci. U.S.A. 103, 16466-16471.
142. Sako, A., Kitayama, J., Koyama, H., Ueno, H., Uchida, H., Hamada, H., and Nagawa, H. (2004). Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer. Cancer Res. 64, 3624-3628.
143. Saleh, M., Stacker, S.A., and Wilks, A.F. (1996a). Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 56, 393-401.
144. Saleh, M., Vasilopoulos, K., Stylli, S.S., Kaye, A.H., and Wilks, A.F. (1996b). The expression of antisense vascular endothelial growth factor (VEGF) sequences inhibits intracranial C6 glioma growth in vivo by suppressing tumour angiogenesis. J. Clin. Neurosci. 3, 366-372. (Pubitemid 126658512)
145. Sallinen, H., Anttila, M., Narvainen, J., Koponen, J., Hamalainen, K., Kholova, I., Heikura, T., Toivanen, P., Kosma, V.M., Heinonen, S., Alitalo, K., and Yla-Herttuala, S. (2009). Anti-angiogenic gene therapy with soluble VEGFR-1,\2, and\3 reduces the growth of solid human ovarian carcinoma in mice. Mol. Ther. 17, 278-284.
146. Samaranayake, H., Wirth, T., Schenkwein, D., Raty, J.K., and Yla-Herttuala, S. (2009). Challenges in monoclonal antibody-based therapies. Ann. Med. 41, 322-331.
147. Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A., Lilenbaum, R., and Johnson, D.H (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550. (Pubitemid 44917502)
148. Sasaki, M., Wizigmann-Voos, S., Risau, W., and Plate, K.H. (1999). Retrovirus producer cells encoding antisense VEGF prolong survival of rats with intracranial GS9L gliomas. Int. J. Dev. Neurosci. 17, 579-591.
149. Sauter, B.V., Martinet, O., Zhang, W.J., Mandeli, J., and Woo, S.L. (2000). Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc. Natl. Acad. Sci. U.S.A. 97, 4802-4807.
150. Scappaticci, F.A., Contreras, A., Smith, R., Bonhoure, L., Lum, B., Cao, Y., Engleman, E.G., and Nolan, G.P. (2001). Statin-AE: A novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity. Angiogenesis 4, 263-268.
151. Schmidt, K., Hoffend, J., Altmann, A., Strauss, L.G., Mitrakopoulou-Strauss, A., Engelhardt, B., Koczan, D., Peter, J. Dengler, T.J., Mier, W., Eisenhut, M., Haberkorn, U., and Kinscherf, R. (2006). Angiostatin overexpression in Morris hepatoma results in decreased tumor growth but increased perfusion and vascularization. J. Nucl. Med. 47, 543-551. (Pubitemid 46768498)
152. Senger, D.R., Galli, S.J., Dvorak, A.M., Perruzzi, C.A., Harvey, V.S., and Dvorak, H.F. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985.
153. 2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 50, 1774-1778.
154. Shibuya, M. (2008). Vascular endothelial growth factor-dependent and-independent regulation of angiogenesis. BMB Rep. 41, 278-286.
155. Shiose, S., Sakamoto, T., Yoshikawa, H., Hata, Y., Kawano, Y., Ishibashi, T., Inomata, H., Takayama, K., and Ueno, H. (2000). Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma. Invest. Ophthalmol. Vis. Sci. 41, 2395-2403.
156. Simon, R.H., Engelhardt, J.F., Yang, Y., Zepeda, M., Weber-Pendleton, S., Grossman, M., and Wilson, J.M. (1993). Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: Toxicity study. Hum. Gene Ther. 4, 771-780. (Pubitemid 24305771)
157. Singh, R.P., and Agarwal, R. (2003). Tumor angiogenesis: A potential target in cancer control by phytochemicals. Curr. Cancer Drug Targets 3, 205-217.
158. Streck, C.J., Dickson, P.V., Ng, C.Y., Zhou, J., Gray, J.T., Nathwani, A.C., and Davidoff, A.M. (2005). Adeno-associated virus vector-mediated systemic delivery of IFN-b combined with low-dose cyclophosphamide affects tumor regression in murine neuro-blastoma models. Clin. Cancer Res. 11, 6020-6029.
159. Strugar, J., Rothbart, D., Harrington, W., and Criscuolo, G.R. (1994). Vascular permeability factor in brain metastases: Correlation with vasogenic brain edema and tumor angiogenesis. J. Neurosurg. 81, 560-566.
160. Subramanian, I.V., Ghebre, R., and Ramakrishnan, S. (2005). Adeno-associated virus-mediated delivery of a mutant en-dostatin suppresses ovarian carcinoma growth in mice. Gene Ther. 12, 30-38.
161. Subramanian, I.V., Bui Nguyen, T.M., Truskinovsky, A.M., Tolar, J., Blazar, B.R., and Ramakrishnan, S. (2006). Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival. Cancer Res. 66, 4319-4328.
162. Sugimoto, H., Hamano, Y., Charytan, D., Cosgrove, D., Kieran, M., Sudhakar, A., and Kalluri, R. (2003). Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J. Biol. Chem. 278, 12605-12608.
163. Tai, K.F., Chen, P.J., Chen, D.S., and Hwang, L.H. (2003). Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors. J. Gene Med. 5, 386-398.
164. Takahashi, S., Kawarabayasi, Y., Nakai, T., Sakai, J., and Yama-moto, T. (1992). Rabbit very low density lipoprotein receptor: A low density lipoprotein receptor-like protein with distinct ligand specificity. Proc. Natl. Acad. Sci. U.S.A. 89, 9252-9256.
165. Takahashi, T., Ueno, H., and Shibuya, M. (1999). VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endo-thelial cells. Oncogene 18, 2221-2230.
166. Takano, S., Yoshii, Y., and Nose, T. (1991). [Ultrastructure of glioma vessel\morphometric study for vascular permeability]. No To Shinkei 43, 49-56.
167. Takano, S., Yoshii, Y., Kondo, S., Suzuki, H., Maruno, T., Shirai, S., and Nose, T. (1996). Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 56, 2185-2190.
168. Takayama, K., Ueno, H., Nakanishi, Y., Sakamoto, T., Inoue, K., Shimizu, K., Oohashi, H., and Hara, N. (2000). Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res. 60, 2169-2177.
169. Takei, Y., Mizukami, H., Saga, Y., Yoshimura, I., Hasumi, Y., Takayama, T., Kohno, T., Matsushita, T., Okada, T., Kume, A., Suzuki, M., and Ozawa, K. (2007). Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1=Flt-1 using adeno-associated virus serotype 1-derived vector. Int. J. Cancer 120, 278-284.
170. Takei, Y., Saga, Y., Mizukami, H., Takayama, T., Ohwada, M., Ozawa, K., and Suzuki, M. (2008). Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice. Mol. Cancer Ther. 7, 704-711.
171. Terman, B.I., Dougher-Vermazen, M., Carrion, M.E., Dimitrov, D., Armellino, D.C., Gospodarowicz, D., and Bohlen, P. (1992). Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187, 1579-1586.
172. Tsai, V., Varghese, R., Ravindran, S., Ralston, R., and Vellekamp, G. (2008). Complement component C1q and anti-hexon antibody mediate adenovirus infection of a CAR-negative cell line. Viral Immunol. 21, 469-476.
173. Uchida, T., Kajiwara, K., Ideguchi, M., Yoshikawa, K., Morioka, J., and Suzuki, M. (2001). Co-administration of adenovirus vector expressing CTLA4-Ig prolongs transgene expression in the brain of mice sensitized with adenovirus. Brain Res. 898, 272-280.
174. Verheul, H.M., and Pinedo, H.M. (2007). Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat. Rev. Cancer 7, 475-485.
175. Wen, X.Y., Bai, Y., and Stewart, A.K. (2001). Adenovirus-mediated human endostatin gene delivery demonstrates strain-specific antitumor activity and acute dose-dependent toxicity in mice. Hum. Gene Ther. 12, 347-358.
176. Winkler, F., Kozin, S.V., Tong, R.T., Chae, S.S., Booth, M.F., Garkavtsev, I., Xu, L., Hicklin, D.J., Fukumura, D., di Tomaso, E., Munn, L.L., and Jain, R.K. (2004). Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553-563.
177. Xiao, F., Wei, Y., Yang, L., Zhao, X., Tian, L., Ding, Z., Yuan, S., Lou, Y., Liu, F., Wen, Y., Li, J., Deng, H., Kang, B., Mao, Y., Lei, S., He, Q., Su, J., Lu, Y., Niu, T., Hou, J., and Huang, M.J. (2002). A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther. 9, 1207-1213.
178. Yang, Y., Nunes, F.A., Berencsi, K., Furth, E.E., Gonczol, E., and Wilson, J.M. (1994). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U.S.A. 91, 4407-4411.
179. Ye, C., Feng, C., Wang, S., Wang, K.Z., Huang, N., Liu, X., Lin, Y., and Li, M. (2004). sFlt-1 gene therapy of follicular thyroid carcinoma. Endocrinology 145, 817-822.
180. Yokoyama, Y., Sedgewick, G., and Ramakrishnan, S. (2007). Endostatin binding to ovarian cancer cells inhibits peritoneal attachment and dissemination. Cancer Res. 67, 10813-10822. (Pubitemid 350145910)
181. Yoon, S.S., Eto, H., Lin, C.M., Nakamura, H., Pawlik, T.M., Song, S.U., and Tanabe, K.K. (1999). Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res. 59, 6251-6256.
182. Yoshimura, I., Mizuguchi, Y., Miyajima, A., Asano, T., Tada-kuma, T., and Hayakawa, M. (2004). Suppression of lung metastasis of renal cell carcinoma by the intramuscular gene transfer of a soluble form of vascular endothelial growth factor receptor I. J. Urol. 171, 2467-2470.
183. Zagzag, D. (1995). Angiogenic growth factors in neural em-bryogenesis and neoplasia. Am. J. Pathol. 146, 293-309.
184. Zhang, Z., Zou, W., Wang, J., Gu, J., Dang, Y., Li, B., Zhao, L., Qian, C., Qian, Q., and Liu, X. (2005). Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an an-tiangiogenic gene, soluble Flt-1. Mol. Ther. 11, 553-562.
185. Zheng, A.Q., Song, X.R., Yu, J.M., Wei, L., and Wang, X.W. (2005). Liposome transfected to plasmid-encoding endostatin gene combined with radiotherapy inhibits liver cancer growth in nude mice. World J. Gastroenterol. 11, 4439-4442.